Abstract
Purpose
Non-opioid analgesics are increasingly used as part of a multimodal regimen for pain management. This prospective, randomized, double-blinded, placebo-controlled study was designed to evaluate the effect of short-term postoperative administration of celecoxib on pain management and recovery outcomes following laparoscopic surgery.
Methods
Eighty consenting ASA I-III outpatients undergoing laparoscopic surgery were randomly assigned to one of two treatment groups: Control (placebo) or Celecoxib (celecoxib, 400 mg·day-1). The initial dose (celecoxib 400 mg or placebopo) was administered in the recovery room, and celecoxib 200 mg (or a placebo)po bid was continued for three additional days after surgery. Postoperative pain scores and the need for opi-oid-containing analgesics were recorded at specific intervals in the recovery room. Follow-up evaluations were performed at 24 hr, 48 hr, 72 hr and seven days and one month after surgery to assess post-discharge pain, analgesic requirements, complications, quality of recovery, and resumption of normal activities, as well as patient satisfaction with their pain management.
Results
Celecoxib reduced mean pain scores and the need for analgesics at 24 hr and 48 hr postoperatively. Patient satisfaction with their postoperative pain management was also higher in the Celecoxib group (94 ± 8 vs 80 ± 25,P < 0.05). Quality of recovery scores were significantly higher in the Celecoxib group on the first and second postoperative days (17 ± 1 vs 15 ± 2, and 18 ± 1 vs 16 ± 2, respectively). Finally, bowel function recovered an average of one day earlier and patients resumed activities of daily living two days earlier in the Celecoxib group (P < 0.05).
Conclusion
Short-term administration of celecoxib, 400 mg·day−1 po, decreased postoperative pain and the need for opioid-containing analgesic medication, leading to an improved quality of recovery after outpatient laparoscopic surgery.
Résumé
Objectif
Les analgésiques non-opiacés sont de plus en plus utilisés dans le cadre d’un régime multimodal pour le traitement de la douleur. Cette étude prospective, randomisée, à double insu et contrôlée par placebo a été effectuée afin de déterminer l’effet de l’administration postopératoire à court terme de célécoxib sur le traitement de la douleur et la convalescence suite à une chirurgie laparoscopique.
Méthode
Quatre-vingt patients ASA I-III non hospitalisés subissant une chirurgie laparoscopique ont été randomisés en deux groupes de traitement : Témoin (placebo) ou Célécoxib (célécoxib, 400 mg·jour−1). La dose initiale (célécoxib 400 mg ou placebo po) a été administrée à la salle de réveil, et l’administration de célécoxib 200 mg (ou un placebo) po a été continuée deux fois par jour pendant trois jours suivant l’opération. La douleur postopératoire et les besoins en analgésiques à base d’opiacés ont été mesurés à des intervalles spécifiques à la salle de réveil. Des examens de contrôle ont été effectués 24 h, 48 h, 72 h, sept jours et un mois après la chirurgie afin d’évaluer la douleur suite au congé de l’hôpital, les besoins analgésiques, les complications, la qualité du rétablissement et la reprise des activités normales, ainsi que la satisfaction des patients quant au traitement de la douleur.
Résultats
Le célécoxib a réduit les scores moyens de douleur ainsi que le besoin d’analgésiques à 24h et 48h après l’opération. La satisfaction des patients quant au traitement postopératoire de la douleur qu’ils ont reçu était également plus élevée dans le groupe célécoxib (94 ±8 vs 80 ± 25,P< 0,05). Les résultats de la qualité du rétablissement étaient significativement plus élevés dans le groupe célécoxib le premier et le deuxième jour après l’opération (17±1vs15±2,et18 ± 1 vs 16 ± 2, respectivement). Finalement, la fonction intestinale a été rétablie en moyenne un jour plus tôt et les patients ont repris leurs activités quotidiennes deux jours plus tôt dans le groupe célécoxib (P < 0,05).
Conclusion
L’administration à court terme de célécoxib 400 mg·jour−1 po a diminué la douleur postopératoire et le besoin de médication analgésique à base d’opiacés, ce qui a engendré une qualité de rétablissement améliorée après la chirurgie laparoscopi-que sans hospitalisation.
Article PDF
Similar content being viewed by others
References
White PF. The role of non-opioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg 2002; 94: 577–85.
Liu J, Ding Y, White PF, Feinstein R, Shear JM. Effects of ketorolac on postoperative analgesia and ventilatory function after laparoscopic cholecystectomy. Anesth Analg 1993; 76: 1061–6.
Coloma M, White PF, Huber PJ Jr,Tongier WK, Dullye KK, Duffy LL. The effect of ketorolac on recovery after anorectal surgery: intravenous versus local administration. Anesth Analg 2000; 90: 1107–10.
Rusy LM, Houck CS, Sullivan LJ, et al. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg 1995; 80: 226–9.
Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg 1994; 79: 1178–90.
Reuben SS, Fingeroth R, Krushell R, Maciolek H. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002; 17: 26–31.
Issioui T, Klein KW, White PF, et al. The efficacy of premedication with celecoxib and acetaminophen in preventing pain after otolaryngologic surgery. Anesth Analg 2002; 94: 1188–93.
Reuben SS, Bhopatkar S, Maciolek H, Joshi W, Sklar J. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002; 94: 55–9.
Issioui T, Klein KW, White PF, et al. Cost-efficacy of rofecoxib versus acetaminophen for preventing pain after ambulatory surgery. Anesthesiology 2002; 97: 931–7.
Watcha MF, Issioui T, Klein KW, White PF. Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. Anesth Analg 2003; 96: 987–94.
Recart A, Issioui T, White PF, et al. The efficacy of celecoxib premedication on postoperative pain and recovery times after ambulatory surgery: a dose-ranging study. Anesth Analg 2003; 96: 1631–5.
Ma H, Tang J, White PF, et al. Perioperative rofecoxib improves early recovery after outpatient herniorrhaphy. Anesth Analg 2004; 98: 970–5.
Gan TJ, Joshi GP, Viscusi E, et al. Preoperative parenteral parecoxib and follow-up oral valdecoxib reduce length of stay and improve quality of patient recovery after laparoscopic cholecystectomy surgery. Anesth Analg 2004; 98: 1665–73.
Ekman EF, Wahba M, Ancona F. Analgesic efficacy of perioperative celecoxib in ambulatory arthroscopic knee surgery: a double-blind, placebo-controlled study. Arthroscopy 2006; 22: 635–42.
Ott E, Nussmeier NA, Duke PC, et al.;Multicenter Study of Perioperative Ischemia (McSPI) Research Group;Ischemia Research and Education Foundation (IREF) Investigators. Efficacy and safety of the cyl-cooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125: 1481–92.
Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081–91.
Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth 1995; 7: 89–91.
MylesPS, Hunt JO, Nightingale CE, et al. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg 1999; 88: 83–90.
Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet 2006; 367: 1618–25.
Nussmeier NA, Whelton AA, Brown MT, et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology 2006; 104: 518–26.
Solomon SD, Pfeffer MA, McMurray JJ, et al.;APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006; 114: 1028–35.
Bresalier RS, Sandler RS, Quan H, et al.;Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092–102.
Zhang J, Ding EL, Song Y. Adverse effects of cyclo-oxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296: 1619–32.
Naesh O. Back to the future: postoperative pain management beyond COX-2 inhibitors. N Z Med J 2006; 119: U2170.
White PF. Changing role of COX-2 inhibitors in the perioperative period: is parecoxib really the answer? Anesth Analg 2005; 100: 1306–8.
Gilron I, Orr E, Tu D, O’Neill JP, Zamora JE, Bell AC. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 2005; 113: 191–200.
Turan A, White PF, Karamanlioglu B, et al. Gabapentin: an alternative to the cyclooxygenase-2 inhibitors for perioperative pain management. Anesth Analg 2006; 102: 175–81.
Reuben SS, Buvanendran A, Kroin JS, Raghunathan K. The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery. Anesth Analg 2006; 103: 1271–7.
White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg 2005; 101(5 Suppl): S5–22.
Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor of pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA 2003; 290: 2411–8.
Sacan O, Romero G, Coleman JE, White PF. Effect of peri- vs postoperative celecoxib administration on recovery after major plastic surgery procedures. Anesthesiology 2005; 103: A977 (abstract).
Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002; 96: 725–41
Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in postoperative pain management: current evidence and future directions. Anesthesiology 2003; 99: 1198–208.
Gajraj NM. Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96: 1720–38.
Author information
Authors and Affiliations
Corresponding author
Additional information
Financial support: This investigator-initiated, FDA-approved study was supported in part by an unrestricted educational grant from Pfizer, Inc. (New York, NY), endowment funds from the Margaret Milam McDermott Distinguished Chair in Anesthesiology, and the White Mountain Institute, a non-profit private foundation (Paul F. White, President).
Rights and permissions
About this article
Cite this article
White, P.F., Sacan, O., Tufanogullari, B. et al. Effect of short-term postoperative celecoxib administration on patient outcome after outpatient laparoscopic surgery. Can J Anesth 54, 342–348 (2007). https://doi.org/10.1007/BF03022655
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03022655